SequelSEC

Vaxart, Inc. VXRT

Biological Products, (No Diagnostic Substances) · CIK 0000072444 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$243.06M
Fiscal year ended 2026-06-30
Operating income
$39.61M
Fiscal year ended 2026-06-30
Free cash flow
$33.38M
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$102.71MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$0.43Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / net income6.3×A lower bound on the multiple, because affiliate holdings are excluded.
Float / revenue0.4×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity1.2×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Biological Products, (No Diagnostic Substances) filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Revenue YoY growth726.7%97th
CapEx / revenue0.1%4th
SBC / revenue3.5%7th
Operating margin7.6%86th
FCF margin3.2%83th
Net margin6.9%83th
Current ratio1.57x23th
R&D / revenue85.0%32th
Effective tax rate2.8%35th

Vaxart, Inc. (VXRT) reported revenue of $243.06M and net income of $38.59M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Vaxart, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

Vaxart, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$243.06M
Cost of revenueUnavailable
Gross profitUnavailable
Operating income$39.61M
Net income$38.59M
Research & development$184.26M
Weighted-average diluted sharesUnavailable
Pretax income$39.01M
Income tax expense$419.00K
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$19.19M
Selling & marketingUnavailable

Balance

Vaxart, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalentsUnavailable
Total assets$165.18M
Current assets$116.69M
Total liabilities$82.81M
Current liabilities$73.11M
Total equity incl. NCI$82.37M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivable$11.00K
Goodwill$4.51M
Long-term debtUnavailable
Accounts payable$16.97M

Cash flow

Vaxart, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow$33.98M
Capital expenditures$601.00K
Investing cash flow-$7.22M
Financing cash flow$4.06M
Net change in cash$30.82M
Stock-based compensation$6.51M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$6.00M

Derived

Vaxart, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow$33.38M
Gross marginUnavailable
Operating margin16.3%
FCF margin13.7%
SBC / revenue2.7%
Current ratio1.60x
Revenue YoY growth201.1%
Net margin15.9%
R&D / revenue75.8%
CapEx / revenue0.2%
Long-term debt / equityUnavailable
Effective tax rate1.1%

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open VXRT in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-06View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-03-13View SEC filing
10-Q · Filed 2025-11-13View SEC filing
10-Q · Filed 2025-08-13View SEC filing
10-Q · Filed 2025-05-13View SEC filing

Companies in the same industry

ABOS ABPO ACOG ADAPY ADMA ADPT AGEN AGTX AIM ALEC ALGS ALLO

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.